- Home
- AMAT vs AMGN Comparison
AMAT vs AMGN Comparison
Compare AMAT & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAT
- AMGN
- Stock Information
- Founded
- AMAT 1967
- AMGN 1980
- Country
- AMAT United States
- AMGN United States
- Employees
- AMAT N/A
- AMGN N/A
- Industry
- AMAT Semiconductors
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMAT Technology
- AMGN Health Care
- Exchange
- AMAT Nasdaq
- AMGN Nasdaq
- Market Cap
- AMAT 162.5B
- AMGN 150.8B
- IPO Year
- AMAT N/A
- AMGN N/A
- Fundamental
- Price
- AMAT $230.51
- AMGN $295.58
- Analyst Decision
- AMAT Buy
- AMGN Hold
- Analyst Count
- AMAT 28
- AMGN 15
- Target Price
- AMAT $211.32
- AMGN $313.57
- AVG Volume (30 Days)
- AMAT 6.9M
- AMGN 2.1M
- Earning Date
- AMAT 11-13-2025
- AMGN 11-04-2025
- Dividend Yield
- AMAT 0.77%
- AMGN 3.21%
- EPS Growth
- AMAT N/A
- AMGN 110.88
- EPS
- AMAT 8.38
- AMGN 12.23
- Revenue
- AMAT $28,613,000,000.00
- AMGN $34,917,000,000.00
- Revenue This Year
- AMAT $6.09
- AMGN $8.82
- Revenue Next Year
- AMAT $2.57
- AMGN $1.84
- P/E Ratio
- AMAT $28.37
- AMGN $24.26
- Revenue Growth
- AMAT 6.55
- AMGN 12.88
- 52 Week Low
- AMAT $123.74
- AMGN $253.30
- 52 Week High
- AMAT $242.50
- AMGN $335.88
- Technical
- Relative Strength Index (RSI)
- AMAT 58.11
- AMGN 54.10
- Support Level
- AMAT $230.45
- AMGN $288.26
- Resistance Level
- AMAT $239.79
- AMGN $301.00
- Average True Range (ATR)
- AMAT 6.58
- AMGN 5.96
- MACD
- AMAT -0.87
- AMGN -0.33
- Stochastic Oscillator
- AMAT 54.77
- AMGN 46.95
About AMAT Applied Materials Inc.
Applied Materials is the largest semiconductor wafer fabrication equipment manufacturer in the world. It has a broad portfolio spanning nearly every corner of the WFE ecosystem. Applied Materials holds leading market share in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.